Premium
Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium
Author(s) -
Yee Sook Wah,
Brackman Deanna J.,
Ennis Elizabeth A.,
Sugiyama Yuichi,
Kamdem Landry K.,
Blanchard Rebecca,
Galetin Aleksandra,
Zhang Lei,
Giacomini Kathleen M.
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1098
Subject(s) - slco1b1 , transporter , pharmacogenomics , solute carrier family , drug , biology , abcg2 , disposition , pharmacology , pharmacogenetics , computational biology , atp binding cassette transporter , genetics , gene , genotype , psychology , social psychology
Advances in genomic technologies have led to a wealth of information identifying genetic polymorphisms in membrane transporters, specifically how these polymorphisms affect drug disposition and response. This review describes the current perspective of the International Transporter Consortium (ITC) on clinically important polymorphisms in membrane transporters. ITC suggests that, in addition to previously recommended polymorphisms in ABCG2 (BCRP) and SLCO1B1 (OATP1B1), polymorphisms in the emerging transporter, SLC22A1 (OCT1), be considered during drug development. Collectively, polymorphisms in these transporters are important determinants of interindividual differences in the levels, toxicities, and response to many drugs.